-
摘要:
前列腺癌是西方国家老年男性常见的恶性肿瘤。近十余年来，中国前列腺癌发病率及死亡率均呈快速上升趋势。随着社会经济、生活方式的变化以及诊断治疗手段的进步，前列腺癌的流行病学特点也在不断变化。因此，了解前列腺癌的流行病学变化特点有助于为科学防治这一恶性肿瘤提供科学依据。本文就中国前列腺癌发病及死亡现状、流行病学分布特征、生存情况以及危险因素等方面的研究进展进行综述。
Abstract:Prostate cancer is a common malignant tumor in elderly men in western countries. In the past decade, the incidence and mortality of prostate cancer in China have shown a rapid upward trend. With the changes of social economy, life style and the progress of diagnosis and treatment, the epidemiological characteristics of prostate cancer are constantly changing. Therefore, understanding the epidemiological characteristics of prostate cancer is helpful to provide scientific basis for prevention and treatment of this malignant tumor. This article reviews the research progress on the morbidity, mortality, epidemiological distribution, survival and risk factors of prostate cancer in China.
-
Key words:
- Prostate cancer /
- Incidence /
- Mortality /
- Epidemiological distribution /
- China
-
Competing interests: The authors declare that they have no competing interests.作者贡献李星：论文撰写与修改曾晓勇：论文审校
-
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2] 顾秀瑛, 郑荣寿, 张思维, 等. 2000-2014年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J].中华预防医学杂志, 2018, 52(6): 586-592. doi: 10.3760/cma.j.issn.0253-9624.2018.06.006 Gu XY, Zheng RS, Zhang SW, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2018, 52(6): 586-592. doi: 10.3760/cma.j.issn.0253-9624.2018.06.006
[3] Qi D, Wu C, Liu F, et al. Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009[J]. Prostate, 2015, 75(14): 1662-1668. doi: 10.1002/pros.23046
[4] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[5] 齐金蕾, 王黎君, 周脉耕, 等. 1990-2013年中国男性前列腺癌疾病负担分析[J].中华流行病学杂志, 2016, 37(6): 778-782. doi: 10.3760/cma.j.issn.0254-6450.2016.06.007 Qi JL, Wang LJ, Zhou MG, et al. Disease burden of prostate cancer among men in China, from 1990 to 2013[J]. Zhonghua Liu Xing Bing Za Zhi, 2016, 37(6): 778-782. doi: 10.3760/cma.j.issn.0254-6450.2016.06.007
[6] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019, 41(1): 19-28. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Zhonghua Zhong Liu Za Zhi, 2019, 41(1): 19-28.
[7] 孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤, 2019, 28(1): 1-11. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201901001.htm Sun KX, Zheng RS, Zhang SW, et al. Report of Cancer Incidence and Mortality in Different Areas of China, 2015[J]. Zhongguo Zhong Liu, 2019, 28(1): 1-11. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201901001.htm
[8] 蒋光昶, 徐娟娟, 黄桂军, 等. 2009-2018年黔南州居民前列腺癌发病和死亡趋势分析[J].现代预防医学, 2019, 46(13): 2488-2491. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYF201913043.htm Jiang GC, Xu JJ, Huang GJ, et al. Morbidity and death trend of prostatic carcinoma, Qiannan, 2009-2018[J]. Xian Dai Yu Fang Yi Xue, 2019, 46(13): 2488-2491. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYF201913043.htm
[9] 丁贤彬, 吕晓燕, 毛德强, 等. 2006-2014年重庆市前列腺癌发病趋势及相关因素[J].现代肿瘤医学, 2016, 24(23): 3819-3822. doi: 10.3969/j.issn.1672-4992.2016.23.037 Ding XB, Lv XY, Mao DQ, et al. A study on incidence trend of prostate cancer and its determinant factors from 2006 to 2014 in Chongqing, China[J]. Xian Dai Zhong Liu Yi Xue, 2016, 24(23): 3819-3822. doi: 10.3969/j.issn.1672-4992.2016.23.037
[10] 朱洪挺, 胡云卿, 李辉章, 等. 2010~2014年浙江省肿瘤登记地区前列腺癌发病与死亡分析[J].中国肿瘤, 2019, 28(2): 110-114. doi: 10.3969/j.issn.1674-4136.2019.02.008 Zhu HT, Hu YQ, Li HZ, et al. Incidence and Mortality of Prostate Cancer in Zhejiang Cancer Registration Areas, 2010-2014[J]. Zhongguo Zhong Liu, 2019, 28(2): 110-114. doi: 10.3969/j.issn.1674-4136.2019.02.008
[11] Liu X, Yu C, Bi Y, et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China[J]. Public Health, 2019, 172: 70-80. doi: 10.1016/j.puhe.2019.04.016
[12] Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates[J]. Eur Urol, 2020, 77(1): 38-52. doi: 10.1016/j.eururo.2019.08.005
[13] 陈万青, 李贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志, 2018, 40(1): 5-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201801001.htm Chen WQ, Li H, Sun KX, et al. Report of Cancer Incidence and Mortality in China, 2014[J]. Zhonghua Zhong Liu Za Zhi, 2018, 40(1): 5-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201801001.htm
[14] 鲍萍萍, 吴春晓, 张敏璐, 等. 2015年上海市恶性肿瘤流行特征分析[J].中国癌症杂志, 2019, 29(2): 81-99. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201902001.htm Bao PP, Wu CX, Zhang ML, et al. Report of cancer epidemiology in Shanghai, 2015[J]. Zhongguo Ai Zheng Za Zhi, 2019, 29(2): 81-99. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201902001.htm
[15] Fitzmaurice C, Abate D, Abbasi N, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2019, 5(12): 1749-1768. doi: 10.1001/jamaoncol.2019.2996
[16] Zhai Z, Zheng Y, Li N, et al. Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017[J]. Cancer, 2020, 126(9): 1969-1978. doi: 10.1002/cncr.32733
[17] 李科, 林国桢, 沈纪川, 等.广州市中心城区2000-2011年前列腺癌发病与死亡趋势分析[J].中华泌尿外科杂志, 2015, 36(3): 213-216. doi: 10.3760/cma.j.issn.1000-6702.2015.03.015 Li K, Lin GZ, Shen JC, et al. Analysis of incidence and mortality of prostate cancer in urban Guangzhou between 2000 and 2011[J]. Zhonghua Mi Niao Wai Ke Za Zhi, 2015, 36(3): 213-216. doi: 10.3760/cma.j.issn.1000-6702.2015.03.015
[18] 何燕, 岳丽梅, 夏劲节, 等. 2016-2018年成都市恶性肿瘤发病率分析[J].预防医学情报杂志, 2019, 35(11): 1268-1274. https://www.cnki.com.cn/Article/CJFDTOTAL-YFYX201911018.htm He Y, Yue LM, Xia JJ, et al. Incidence Rates of Malignant Tumor in Chengdu City From 2016 to 2018[J]. Yu Fa Yi Xue Qing Bao Za Zhi, 2019, 35(11): 1268-1274. https://www.cnki.com.cn/Article/CJFDTOTAL-YFYX201911018.htm
[19] 闫贻忠, 冯凯旋, 王新宇, 等.新疆石河子地区2009~2017年前列腺癌流行趋势分析[J].中华男科学杂志, 2019, 25(1): 35-40. https://www.cnki.com.cn/Article/CJFDTOTAL-NKXB201901007.htm Yan YZ, Feng KX, Wang XY, et al. Trend in the prevalence of prostate cancer in Shihezi, Xinjiang from 2009 to 2017[J]. Zhonghua Nan Ke Xue Za Zhi, 2019, 25(1): 35-40. https://www.cnki.com.cn/Article/CJFDTOTAL-NKXB201901007.htm
[20] 周伟, 陈奇峰.浙江省绍兴市2009-2014年前列腺癌发病和死亡情况及变化趋势[J].中华泌尿外科杂志, 2015, 36(12): 905-909. doi: 10.3760/cma.j.issn.1000-6702.2015.12.007 Zhou W, Chen QF. Trend of incidence and mortality on prostate cancer from 2009 to 2014 in Shaoxing, Zhejiang Province[J]. Zhonghua Mi Niao Wai Ke Za Zhi, 2015, 36(12): 905-909. doi: 10.3760/cma.j.issn.1000-6702.2015.12.007
[21] 李小攀, 杨琛, 孙乔, 等. 2002-2013年上海市浦东新区居民前列腺癌发病死亡趋势分析[J].中华肿瘤防治杂志, 2015, 22(6): 412-415. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201506004.htm Li XP, Yang C, Sun Q, et al. Trends analysis on the morbidity and mortality of prostate cancer among residents in Pudong New Area of Shanghai, 2002-2013[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2015, 22(6): 412-415. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201506004.htm
[22] United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, custom data acquired via website: https://population.un.org/wpp/DataQuery/.
[23] 林恒娜, 顾秀瑛, 张思维, 等.全球恶性肿瘤发病年龄分析[J].中华肿瘤杂志, 2018, 40(7): 543-549. doi: 10.3760/cma.j.issn.0253-3766.2018.07.012 Lin HN, Gu XY, Zhang SW, et al. Analysis on incidence and mean age at diagnosis for Global Cancer[J]. Zhonghua Zhong Liu Za Zhi, 2018, 40(7): 543-549. doi: 10.3760/cma.j.issn.0253-3766.2018.07.012
[24] Gu X, Zheng R, Xia C, et al. Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis[J]. Cancer Commun (Lond), 2018, 38(1): 44. doi: 10.1186/s40880-018-0308-x
[25] 屈小骅, 舒心雨, 温鲤键, 等.新疆维汉两族间前列腺癌发病趋势及AMACR表达差异的研究[J].中国实验诊断学, 2016, 20(6): 976-977. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD201606034.htm Qu XH, Shu XY, Wen LJ, et al. Study on the incidence trend of Prostate Cancer and the difference of AMACR expression between Uygur and Han nationalities in Xinjiang[J]. Zhongguo Shi Yan Zhen Duan Xue, 2016, 20(6): 976-977. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD201606034.htm
[26] 吾甫尔·卡德尔, 多尔坤·沙依热木.哈密地区汉族与维吾尔族前列腺癌患者多因素差异研究[J].新疆医学, 2015, 45(11): 1592-1594. https://www.cnki.com.cn/Article/CJFDTOTAL-XJYI201511004.htm WUFUER·kadeer, DUOERKUN·shayiremu. A study on the difference between Han and Uygur patients with prostate cancer at Hami[J]. Xin Jiang Yi Xue, 2015, 45(11): 1592-1594. https://www.cnki.com.cn/Article/CJFDTOTAL-XJYI201511004.htm
[27] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. doi: 10.1016/S2214-109X(18)30127-X
[28] 李小升, 赵玉兰, 陈习田, 等.前列腺癌患者生存随访数据分析[J].中国病案, 2019, 20(11): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGBN201911039.htm Li XS, Zhao YL, Chen XT, et al. Follow-up Data Study on Survival of Prostate Cancer Patients[J]. Zhongguo Bing An, 2019, 20(11): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGBN201911039.htm
[29] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
[30] Xu L, Wang J, Guo B, et al. Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China[J]. Oncotarget, 2018, 9(1): 428-441. doi: 10.18632/oncotarget.20787
[31] Barsouk A, Padala SA, Vakiti A, et al. Epidemiology, Staging and Management of Prostate Cancer[J]. Med Sci (Basel), 2020, 8(3): E28.
[32] Ha Chung B, Horie S, Chiong E. The incidence, mortality, and risk factors of prostate cancer in Asian men[J]. Prostate Int, 2019, 7(1): 1-8.
[33] Wei Y, Wu J, Gu W, et al. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients[J]. Eur Urol, 2019, 76(3): 280-283.
[34] Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations[J]. Nature, 2020, 580(7801): 93-99.
[35] Applegate CC, Rowles JL, Ranard KM, et al. Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis[J]. Nutrients, 2018, 10(1): 40.
[36] Key TJ, Bradbury KE, Perez-Cornago A, et al. Diet, nutrition, and cancer risk: what do we know and what is the way forward?[J]. BMJ, 2020, 368: m511.
[37] Rowles JL, Ranard KM, Smith JW, et al. Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis[J]. Prostate Cancer Prostatic Dis, 2017, 20(4): 361-377.
[38] Morgia G, Voce S, Palmieri F, et al. Association between selenium and lycopene supplementation and incidence of prostate cancer: Results from the post-hoc analysis of the procomb trial[J]. Phytomedicine, 2017, 34: 1-5.
计量
- 文章访问数: 13503
- HTML全文浏览量: 944
- PDF下载量: 6625
下载:
